Vestmark Advisory Solutions Inc. Makes New $414,000 Investment in Grifols, S.A. $GRFS

Vestmark Advisory Solutions Inc. purchased a new stake in Grifols, S.A. (NASDAQ:GRFS) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 45,820 shares of the biotechnology company’s stock, valued at approximately $414,000.

Other hedge funds also recently modified their holdings of the company. R Squared Ltd bought a new stake in shares of Grifols in the second quarter worth $95,000. Ballentine Partners LLC acquired a new position in Grifols during the 1st quarter worth about $77,000. Bessemer Group Inc. lifted its holdings in Grifols by 1,693.8% during the 2nd quarter. Bessemer Group Inc. now owns 11,821 shares of the biotechnology company’s stock worth $107,000 after buying an additional 11,162 shares during the period. Ascent Group LLC bought a new stake in shares of Grifols in the 2nd quarter valued at about $141,000. Finally, Cerity Partners LLC increased its stake in shares of Grifols by 22.8% in the first quarter. Cerity Partners LLC now owns 22,254 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 4,129 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GRFS. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a research note on Wednesday, October 8th. Zacks Research lowered shares of Grifols from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Wall Street Zen downgraded shares of Grifols from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 11th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Grifols in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.30.

Grifols Stock Up 1.5%

Grifols stock opened at $8.73 on Wednesday. The company has a market capitalization of $6.00 billion, a PE ratio of 45.95, a PEG ratio of 0.32 and a beta of 0.69. Grifols, S.A. has a 12-month low of $6.19 and a 12-month high of $11.14. The firm’s fifty day moving average is $9.56 and its 200 day moving average is $9.27. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.